Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Noffar Bar,Maria Victoria Mateos,Paz Ribas,Markus Hansson,Laura Paris,Craig C. Hofmeister,Paula Rodriguez Otero, Maria Aranzazu Bermudez,Thomas Martin,Armando Santoro,Andrew J. Yee,Maria Creignou, Cristina Encinas Rodriguez,Claudio Cerchione,Javier De La Rubia,Albert Oriol,Heidi Waibel,Britta Besemer,Ethan Thompson, Brian Kiesel, Jinjie Chen, Alexander Chung,Isaac W. Boss,Allison Gaudy,Shaoyi Li, Kevin Hsu, Colin Godwin,Michael R. Burgess,Jesus San-Miguel,Luciano Costa BLOOD（2023）
AI 理解论文
溯源树
样例
